Lipomics Technologies to Partner With UC San Diego in Insulin Resistance and Weight Loss Research
Posted on: Monday, 16 July 2007, 09:13 CDT
Lipomics Technologies, Inc., a privately held company that specializes in clinical diagnostic development, announced today that it has entered into an agreement with The University of California, San Diego. The collaboration will focus on clinical investigations aimed at identifying mechanisms underlying the pathogenesis of non-insulin dependent diabetes mellitus (NIDDM), obesity, and other disorders of insulin resistance. Studies are also in progress to identify the relative role of each organ system (muscle, liver and fat) to the pathophysiology of NIDDM.
The company will collaborate on basic and clinical research programs from the lab of Jerrold Olefsky, MD, Associate Dean for Scientific Affairs at the University. "I am very enthusiastic about this new collaboration and think that the data generated through the Lipomics technology will help advance our scientific work," said Dr. Olefsky.
"This collaboration is of special strategic interest to us as we continue to establish our clinical diagnostic development programs. We are very pleased to be working with Dr. Olefsky and the University of California, San Diego," said Meeta Patnaik, chief medical officer at Lipomics.
Lipomics will retain certain rights to develop diagnostic applications based on the data from the studies. Lipomics seeks to partner with academic institutions and drug companies to advance its goal of developing diagnostic tests for metabolic diseases.
About Lipomics
Lipomics Technologies provides industry-leading metabolic assessments for drug research, clinical diagnostics and personalized medicine. The Company's proprietary analytical technologies generate comprehensive, accurate and quantitative profiles of lipid metabolites.
A broad range of bioinformatics and analytical tools map these profiles to the underlying biochemical pathways. Through these tools, Lipomics delivers deep and rich knowledge about biological and metabolic changes induced by disease, drug action, nutritional or lifestyle influences.
In partnership with pharmaceutical, biotechnology and nutrition companies, Lipomics uses its technologies to discover new diagnostic biomarkers, improve drug discovery, develop companion diagnostics and enable individualized health management.
More information about Lipomics can be found at www.lipomics.com.
EDITORIAL CONTACTS: Sarina Chohan (916) 371-7974 Email Contact Agency Contact Doug Forsyth Alchymia Communications® (541) 482-8744 Email Contact
SOURCE: Lipomics Technologies, Inc.
Source: MARKET WIRE
Related Articles
- Ensemble Discovery Corp. And Roche Initiate Product Development Program to Advance New Diagnostic Technology to Optimize Cancer Therapy
- Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests
- Lipomics and Joslin Diabetes Center Collaborate in Insulin Research
- Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
- Clinquest Group Acquires Rights on Clinical Stage Anti-Inflammatory Peptide From University of Utrecht
- Ensemble Discovery and Roche Initiate Research Collaboration to Apply New Diagnostic Technology to Optimize Cancer Therapy
- Clinical Data, Inc. Announces Collaborative Research Agreement With University of Pittsburgh Cancer Institute for Metabolomics Analysis of Lung Cancer Samples
- Luminex Corporation Awarded Frost & Sullivan 2005 Clinical Diagnostics Technology of the Year
- OraSure Receives HCV Patent License From Ortho-Clinical Diagnostics and Chiron Corporation; OraSure to Develop and Commercialize Rapid HCV Test
- Research and Markets: Molecular Biomarkers for Clinical Diagnostics and Drug Discovery and Development
 |
 |
User Comments (0)
RSS Feeds